Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia

Blood

Volumn 102, Issue 9, 2003, Pages 3085-3092

  Kerlin, Bryce A ^c   Yan, S Betty ^b   Isermann, Berend H ^c   Brandt, John T ^c   Sood, Rashmi ^c   Basson, Bruce R ^c   Joyce, David E ^c   Weiler, Hartmut ^a   Dhainaut, Jean Francois ^c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; DROTRECOGIN; PLACEBO; PROTEIN C;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASEPSIS; BLOOD CLOTTING DISORDER; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENDOTOXEMIA; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LD 50; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; MORTALITY; MOUSE; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL; SYSTEMIC DISEASE; THROMBOGENESIS; WILD TYPE;

EID: 0142245617     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-1789     Document Type: Article

References (48)

1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-150.
2. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765-3777.
3. Zoller B, Holm J, Dahlback B. Resistance to activated protein C due to a factor V gene mutation: the most common inherited risk factor of thrombosis. Trends Cardiovasc Med. 1996;6:45-53.
4. de Stefano V, Leone G. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica. 1995;80:344-356.
5. Pawar A, Ghosh K, Shetty S, Colah R, Mohanty D. High frequency of factor V Leiden mutation in Parsis-highly endogamous population in India. Thromb Haemost, 2000;83:965.
6. Yang TL, Cui J, Rehumtulla A, et al. The structure and function of murine factor V and its inactivation by protein C. Blood. 1998;91:4593-4599.
7. Hiyoshi M, Hashimoto S, Tagawa S, Arnutti P, Prayoonwiwat W, Tatsumi N. A Thai patient with the mutation of Arg306 of FV gene identical to the Hong Kong but not to the Cambridge type. Thromb Haemost. 1999;82:1553-1554.
8. Franco RF, Elion J, Tavella MH, Santos SE, Zago MA. The prevalence of factor V Arg306-Thr (factor V Cambridge) and factor V Arg306-Gly mutations in different human populations. Thromb Haemost. 1999;81:312-313.
9. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 1998;91:1135-1139.
10. Majerus PW. Bad blood by mutation. Nature. 1994;369:14-15.
11. Hajjar KA. Factor V Leiden-an unselfish gene? N Engl J Med. 1994;331:1585-1587.
12. Lindqvist PG, Svensson PJ, Dahlback B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss-a possible evolutionary selection mechanism. Thromb Haemost. 1998;79:69-73.
13. Donahue BS, Gailani D, Higgins MS, Drinkwater DC, George AL. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation. 2003;107:1003-1008.
14. Gopel W, Ludwig M, Junge AK, Kohlmann T, Diedrich K, Moller J. Selection pressure for the factor-V-Leiden mutation and embryo implantation. Lancet. 2001;358:1238-1239.
15. Taylor FB, Chank A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Invest 1987;79:918-925.
16. Taylor FB, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood. 2001;97:1685-1688.
17. Bernard GR, Vincent JL, Laterre PF, et al, PROWESS sepsis study group: efficacy and safety of recombinant human activated protein C for treatment of patients with severe sepsis. N Engl J Med. 2001;344:699-709.
18. Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M. Effect of the factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J. 1999;18:893-896.
19. Taylor FB, Chang A, Hinshaw LB, Esmon CT, Archer LT, Beller BK. A model for thrombin protection against endotoxin. Thromb Res. 1984;36: 177-185.
20. Warren BL, Eid A, Singer P, et al, for the Kyber-Sept trial study group. High-dose antithrombin III in severe sepsis: a randomzied controlled trial. JAMA. 2001;286:1869-1878.
21. Abraham E, Reinhart K, Opal SM, et al, for the OPTIMIST trial study group. Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. JAMA. 2003;290:238-247.
22. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 2001;120:915-922.
23. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345: 408-416.
24. Altman DG, Schulz KF, Moher D, et al, for the CONSORT group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-694.
25. Macias WL, Dhainaut JF, Yan SB, et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) (recombinant human activated protein C) in patients with severe sepsis. Clin Pharmacol Ther. 2002;72:391-401.
26. Cui J, Eitzman DT, Westrick RJ, et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood. 2000;96:4222-4226.
27. Weiler H, Lindner V, Kerlin B, et al. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol. 2001;21: 1531-1537.
28. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 1998;101:1983-1991.
29. Isermann B, Hendrickson SB, Hutley K, Wing M, Weiler H. Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. Development. 2001;128:827-838.
30. Taylor FB, Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia colisepsis. Blood. 2000;95:1680-1686.
31. Dahlback B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis: functional tests and DNA-based assays, pros and cons. Thromb Haemost. 1995;73:739-742.
32. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306Thr) associated with resistance to activated protein C. Blood. 1998;91:1140-1144.
33. Franco RF, Maffei FH, Lourenco D, et al. Factor V Arg306-Thr (factor V Cambridge) and factor V Arg306-Gly mutations in venous thrombotic disease. Br J Haematol. 1998;103:888-890.
34. Vincent JL, Moreno R, Takata J, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707-710.
35. Conway EM, van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappa B and mitogen-activated protein kinase pathways. J Exp Med. 2002; 196:565-577.
36. Dahlback B. New molecular insights into the genetics of thrombophilia: resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995;74:139-148.
37. Olson S. Seeking the signs of selection. Science. 2002;298:1324-1325.
38. Echtenacher B, Weigl K, Lehn N, Mannel DN. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun. 2001;69:3550-3555.
39. Mesters RM, Helterbrand J, Utterback BG, et al. Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications. Crit Care Med. 2000;28:2209-2216.
40. Bernard GR, Ely EW, Wright TJ, et al, rhAPC Sepsis Study Group. Safety and dose-relationship of recombinant human activated protein C (rhAPC) on coagulopathy in severe sepsis. Crit Care Med. 2001;29:2051-2059.
41. Liaw PCY, Ferrell G, Esmon CT. A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J Thromb Haemost. 2003;1:662-670.
42. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med. 2001;29 (suppl):S69-S74.
43. Kalil AC, Turlo MA, Um J, Coyle SM, Calvano SE, Lowry SF. Drotrecogin alfa (activated) in a human endotoxin model [abstract]. Crit Care Med 2002; 30:A105.
44. Vincent JL, Angus DC, Artigas A, et al, for the recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) study group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003;31:834-840.
45. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199-11203.
46. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-1882.
47. de Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost. 1998;24:367-379.
48. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation (on behalf of the scientific subcommittee on disseminated intravascular coagulation [DIC] of the International Society on Thrombosis and Haemostasis [ISTH]). Thromb Haemost. 2001;86:1327-1330.